Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6090 + SYS6043 + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Suzhou Xinnuowei Pharmaceutical Technology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SYS6090 + SYS6043 + bevacizumab is an investigational combination regimen developed by CSPC Megalith Biopharmaceutical (a subsidiary of CSPC Pharmaceutical Group) for the treatment of advanced hepatocellular carcinoma (HCC). The regimen leverages three distinct therapeutic modalities: **SYS6090**, a recombinant humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor to enhance antitumor T-cell responses; **SYS6043**, an antibody-drug conjugate (ADC) targeting B7-H3 (CD276), which is overexpressed in various solid tumors, delivering a cytotoxic topoisomerase I inhibitor payload directly to tumor cells; and **bevacizumab**, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) to suppress tumor angiogenesis. This triplet combination is currently being evaluated in Phase Ib/II clinical trials to assess its safety, tolerability, and efficacy, aiming to provide a synergistic therapeutic effect by combining immune checkpoint inhibition, targeted chemotherapy, and anti-angiogenic therapy.
- Other names
- SYS6090 Injection + SYS6043 Injection + bevacizumab
02
Targets
B7-H3IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on SYS6090 + SYS6043 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6090 + SYS6043 + bevacizumab.